Dennis Ding
Stock Analyst at Jefferies
(2.18)
# 3,179
Out of 5,182 analysts
17
Total ratings
41.67%
Success rate
11.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Downgrades: Hold | $30 → $22 | $21.65 | +1.62% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $43 → $40 | $15.29 | +161.61% | 1 | Mar 19, 2026 | |
| SGP SpyGlass Pharma | Initiates: Buy | $62 | $23.52 | +163.61% | 1 | Mar 3, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Hold | $16 → $15 | $14.49 | +0.07% | 2 | Jan 22, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $27.85 | -28.19% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $26.99 | -3.67% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $38.62 | +42.41% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.89 | +323.28% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $27.52 | +27.18% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.28 | +63.55% | 2 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $8 → $6 | $3.48 | +72.41% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $46.22 | -52.40% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $30.45 | -21.18% | 1 | Dec 19, 2022 |
Amphastar Pharmaceuticals
Apr 21, 2026
Downgrades: Hold
Price Target: $30 → $22
Current: $21.65
Upside: +1.62%
Olema Pharmaceuticals
Mar 19, 2026
Assumes: Buy
Price Target: $43 → $40
Current: $15.29
Upside: +161.61%
SpyGlass Pharma
Mar 3, 2026
Initiates: Buy
Price Target: $62
Current: $23.52
Upside: +163.61%
Amicus Therapeutics
Jan 22, 2026
Downgrades: Hold
Price Target: $16 → $15
Current: $14.49
Upside: +0.07%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $27.85
Upside: -28.19%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $26.99
Upside: -3.67%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $38.62
Upside: +42.41%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.89
Upside: +323.28%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $27.52
Upside: +27.18%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.28
Upside: +63.55%
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $3.48
Upside: +72.41%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $46.22
Upside: -52.40%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $30.45
Upside: -21.18%